OC000459 Bronchial Allergen Challenge
Launched by OXAGEN LTD · Jan 25, 2010
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Known history of asthma (intermittent wheezing, cough, dyspnoea responsive to inhaled short acting beta agonists).
- • FEV1 \>65% of predicted on at least two occasions at screening.
- • At the screening allergen challenge, a decrease in FEV1 of ≥20% in the early asthmatic reaction and of ≥15% in the LAR to allergen on 3 separate occasions between 3-10hrs post allergen, 2 of which must be consecutive.
- • No steroid usage in the past 12 weeks.
- • Testing positive to skin prick challenge with at least one of the following allergens: house dust mite, pollen or cat hair within the previous 12 months.
- • Non smokers for a minimum of 6 months; less than 10 pack year history.
- Exclusion Criteria:
- • Respiratory tract pathology other than allergic asthma.
- • Lower respiratory tract infection within 4 weeks prior to an allergen challenge.
- • Receipt of prescribed or OTC medication other than paracetamol or short acting inhaled beta agonists within 14 days of screening or of the first day of each dosing period.
About Oxagen Ltd
Oxagen Ltd. is a biopharmaceutical company dedicated to advancing the development of innovative therapies for unmet medical needs, particularly in the fields of rare and chronic diseases. With a strong focus on precision medicine and genetic research, Oxagen leverages cutting-edge technology and scientific expertise to identify and validate novel drug targets. The company's commitment to rigorous clinical testing and regulatory compliance ensures that its therapeutic candidates are both safe and effective, ultimately aiming to improve patient outcomes and enhance quality of life. Through strategic partnerships and collaborations, Oxagen strives to accelerate the translation of research discoveries into impactful treatments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Manchester, , United Kingdom
Patients applied
Trial Officials
David Singh, MD
Principal Investigator
Medicines Evaluation Unit, Manchester, UK
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials